Stocks · News reference
Cantor Fitzgerald analyst Sarah James maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $13 to $5.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, CVRx (NASDAQ:CVRX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and
Filed: 2026-09-21 AccNo: 0001104659-26-109304 Size: 247 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular